Showing results (1661-1670 of 2,234) with videos related to
Sort By:
Pageof 224
Cancer Biotherapy & Radiopharmaceuticals|July 11, 2026
Personalized Radionuclide Therapy via Avidin-Biotin Pretargeting: Biodistribution and Dosimetry of 177Lu-DOTA-biotin with AvidinOX™ in Solid TumorsFreddy Gonzalez, Vivek Subbiah, S Cheenu Kappadath, et al.Cancer Biotherapy & Radiopharmaceuticals|July 23, 2026
Development of a 177Lu-Labeled Glypican-3-Targeted Antibody Radiopharmaceutical for Adjuvant Radionuclide Therapy Following Hepatocellular Carcinoma ResectionKe FangCancer Biotherapy & Radiopharmaceuticals|August 1, 2026
Lactylation Signatures as Predictors of Prognosis and Therapeutic Response in Lung Adenocarcinoma: Implications for Ultrasound-Based Therapeutic StrategiesQingchun Cai, Chenglu Huang, Yu Huang, et al.Cancer Biotherapy & Radiopharmaceuticals|July 30, 2026
Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy SelectionPengfei Xu, Xianfu Lin, Yunhai Zhu, et al.Cancer Biotherapy & Radiopharmaceuticals|September 17, 2026
Theranostic Radiopharmaceutical-Guided Robotic Surgery for Precision Tumor Resection and Targeted Elimination of Residual Disease in Digestive System MalignanciesYu Wen, Pan Xue, Yinchun Wang, et al.Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude miceD A Vallera, M Elson, M W Brechbiel, et al.Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Impact of scatter and attenuation corrections for iodine-131 two-dimensional quantitative imaging in patientsGrégory Delpon, Ludovic Ferrer, Albert Lisbona, et al.Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Crypt cell dosimetry for 99Tcm-sestamibi in a new small intestinal dosimetry modelLena Jönsson, Xiaowei Liu, Bo-Anders Jönsson, et al.Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferationInga Buchmann, Andreas T J Vogg, Gerhard Glatting, et al.Cancer Biotherapy & Radiopharmaceuticals|January 6, 2011
Releasing the brake on the immune system: ipilimumab in melanoma and other tumorsAhmad Tarhini, Ernest Lo, David R MinorPageof 224